BioCentury | Sep 9, 2002
Company News

Oryx, Novartis deal

...Specialty pharma company Oryx acquired Canadian rights to NVS's Anafranil clomipramine to treat depression and obsessive...
BioCentury | Sep 3, 2002
Company News

Novartis, Oryx CNS deal

...Specialty pharma company Oryx Pharmaceuticals (Mississauga, Ontario) acquired Canadian rights to Anafranil clomipramine from Novartis (NVS...
BioCentury | Dec 4, 2000
Company News

Cephalon, Novartis sales and marketing update

...U.K. four NOVN products: Tegretol carbamazepine to treat epilepsy, Ritalin methylphenidate for attention deficit/hyperactivity disorder, Anafranil...
BioCentury | Nov 27, 2000
Top Story

Cephalon in CNS deal with Novartis in U.K.

...products in the U.K.: Tegretol carbamazepine to treat epilepsy, Ritalin methylphenidate for attention deficit/hyperactivity disorder, Anafranil...
BioCentury | May 5, 1997
Strategy

How CoCensys plans life after Novartis

...for development came primarily from profits resulting from COCN's sale of Novartis drugs such as Anafranil...
BioCentury | Nov 6, 1995
Strategy

CoCensys pushes into psychiatrics

...market three of Ciba’s CNS drugs —Anafranil...
...been replaced by newer generation drugs and Anafranil...
...market three of Ciba’s CNS drugs —Anafranil...
BioCentury | Jul 18, 1994
Company News

CoCensys sales and marketing update

...Ciba-Geigy Ltd. signed agreements under which COCN will co-promote several of Ciba's CNS drugs, including Anafranil...
BioCentury | May 23, 1994
Strategy

Three-pronged COCN-Ciba deal

...co-promotion rights in the U.S. to four of Ciba's central nervous system drugs, including Anafranil (clomipramine hydrochloride...
Items per page:
1 - 8 of 8